Published in Magn Reson Med on September 01, 2006
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A (2010) 3.03
Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A (2007) 2.99
Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology (2009) 1.89
Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol (2009) 1.65
The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J Lipid Res (2008) 1.52
Intracranial plaque enhancement in patients with cerebrovascular events on high-spatial-resolution MR images. Radiology (2014) 1.35
Parahydrogen-induced polarization (PHIP) hyperpolarized MR receptor imaging in vivo: a pilot study of 13C imaging of atheroma in mice. NMR Biomed (2011) 1.27
Multimodal CARS microscopy determination of the impact of diet on macrophage infiltration and lipid accumulation on plaque formation in ApoE-deficient mice. J Lipid Res (2010) 1.10
Imaging atherosclerosis and vulnerable plaque. J Nucl Med (2010) 1.10
A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest (2008) 1.09
An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis (2009) 1.08
Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug Chem (2009) 1.05
Macrophages heterogeneity in atherosclerosis - implications for therapy. J Cell Mol Med (2010) 1.05
Targeted probes for cardiovascular MRI. Future Med Chem (2010) 1.02
Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Med Chem (2010) 0.99
Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging (2009) 0.99
Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles. Mol Pharm (2013) 0.98
Advances in clinical applications of cardiovascular magnetic resonance imaging. Heart (2008) 0.96
Inflammation and neovascularization intertwined in atherosclerosis: imaging of structural and molecular imaging targets. Circulation (2014) 0.95
Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. Int J Nanomedicine (2012) 0.95
Molecular imaging of inflammation and intraplaque vasa vasorum: a step forward to identification of vulnerable plaques? J Nucl Cardiol (2010) 0.93
Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer. Bioconjug Chem (2012) 0.93
Preparation and initial characterization of biodegradable particles containing gadolinium-DTPA contrast agent for enhanced MRI. Proc Natl Acad Sci U S A (2008) 0.93
Molecular imaging in cardiovascular disease: targets and opportunities. Nat Rev Cardiol (2009) 0.91
Biomarkers of atherosclerosis and the potential of MRI for the diagnosis of vulnerable plaque. MAGMA (2007) 0.90
MR-optical imaging of cardiovascular molecular targets. Basic Res Cardiol (2008) 0.89
Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia (2007) 0.86
Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.86
Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2013) 0.85
Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.84
Role of computed tomography voxel size in detection and discrimination of calcium and iron deposits in atherosclerotic human coronary artery specimens. J Comput Assist Tomogr (2009) 0.84
Quantitative cardiovascular magnetic resonance for molecular imaging. J Cardiovasc Magn Reson (2010) 0.84
Recent developments and new perspectives on imaging of atherosclerotic plaque: role of anatomical, cellular and molecular MRI part III. Int J Cardiovasc Imaging (2010) 0.81
Quantum dot mediated imaging of atherosclerosis. Nanotechnology (2009) 0.80
Monocyte-targeting supramolecular micellar assemblies: a molecular diagnostic tool for atherosclerosis. Adv Healthc Mater (2014) 0.79
Gadolinium-Based Contrast Agents for Vessel Wall Magnetic Resonance Imaging (MRI) of Atherosclerosis. Curr Cardiovasc Imaging Rep (2012) 0.79
Composite MR Contrast Agents for Conditional Cell-Labeling. Int J Imaging Syst Technol (2008) 0.79
Determination of edema in porcine coronary arteries by T2 weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2011) 0.79
Facile synthesis of 1-(acetic acid)-4,7,10-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraaza-cyclododecane: a reactive precursor chelating agent. Tetrahedron Lett (2009) 0.79
Strategies for the preparation of bifunctional gadolinium(III) chelators. Curr Org Synth (2011) 0.78
Early identification of aortic valve sclerosis using iron oxide enhanced MRI. J Magn Reson Imaging (2010) 0.78
Molecular imaging in cardiovascular disease: Which methods, which diseases? J Nucl Cardiol (2013) 0.77
Off-resonance saturation MRI of superparamagnetic nanoprobes: theoretical models and experimental validations. J Magn Reson (2011) 0.77
Molecular MRI of Atherosclerotic Plaque With Targeted Contrast Agents. Curr Cardiovasc Imaging Rep (2009) 0.77
Molecular imaging of macrophage enzyme activity in cardiac inflammation. Curr Cardiovasc Imaging Rep (2014) 0.77
MR and Targeted Molecular MRI of Vulnerable Plaques. Interv Neurol (2013) 0.76
Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents. Nanomedicine (Lond) (2015) 0.76
Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging. Curr Med Chem (2015) 0.75
Non-invasive detection of vulnerable coronary plaque. World J Cardiol (2011) 0.75
CTHRSSVVC Peptide as a Possible Early Molecular Imaging Target for Atherosclerosis. Int J Mol Sci (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
MiR-33 contributes to the regulation of cholesterol homeostasis. Science (2010) 6.93
The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol (2003) 6.34
Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA (2005) 5.83
The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol (2013) 4.81
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2010) 4.56
ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature (2011) 4.34
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest (2011) 4.21
Imaging of atherosclerotic cardiovascular disease. Nature (2008) 4.14
Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol (2013) 3.85
Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A (2004) 3.85
Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med (2007) 3.40
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol (2006) 3.36
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A (2011) 3.35
Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol (2005) 3.34
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol (2013) 3.25
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A (2005) 3.15
Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol (2013) 3.07
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A (2006) 3.00
Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A (2007) 2.99
Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett (2008) 2.98
The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol (2012) 2.69
Training cardiovascular fellows in cardiovascular magnetic resonance and vascular imaging; Current status following the core cardiovascular training symposium (COCATS-2) guidelines. J Am Coll Cardiol (2004) 2.67
Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovasc Imaging (2009) 2.56
Cotranslocational degradation protects the stressed endoplasmic reticulum from protein overload. Cell (2006) 2.54
Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med (2008) 2.52
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study. JACC Cardiovasc Imaging (2012) 2.50
Neovascularization in human atherosclerosis. Circulation (2006) 2.44
Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology (2010) 2.43
Recipes for creating animal models of diabetic cardiovascular disease. Circ Res (2007) 2.34
(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol (2007) 2.32
OCT-based diagnosis and management of STEMI associated with intact fibrous cap. JACC Cardiovasc Imaging (2013) 2.31
Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation (2004) 2.30
Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med (2003) 2.29
Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity (2004) 2.27
Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol (2005) 2.23
Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A (2003) 2.23
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation (2004) 2.16
HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A (2011) 2.16
ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Cardiovasc Electrophysiol (2002) 2.14